Group 1 - The core point of the article is that TuoJing Life plans to acquire a controlling stake of 82% in Wuhan Kanglu Biological by first purchasing 72.86% of its shares, with a total transaction amount of 328 million yuan [1][2] - The acquisition is structured in three phases, with the final phase expected to be completed by 2027, contingent upon meeting certain preconditions [1][2] - Wuhan Kanglu Biological specializes in the FISH and PCR molecular diagnostic fields, having received multiple NMPA approvals for its medical devices, indicating a strong regulatory standing [2] Group 2 - In the first five months of 2025, Wuhan Kanglu Biological reported a revenue of 36.54 million yuan and a net profit of 6.86 million yuan, showcasing its financial performance [2] - The valuation of Wuhan Kanglu Biological reflects an increase of 278 million yuan, with a growth rate of 226.53%, attributed to its focus on major diseases and strong marketing channels [2] - The sellers have committed to achieving a total net profit of no less than 91.5 million yuan from 2025 to 2027, with R&D expenses being at least 10% of annual revenue [2][3] Group 3 - The funding for the acquisition will come from the company's own funds and bank loans, with payments made in installments based on the transaction progress, ensuring minimal impact on cash flow [3] - If the performance commitments are met, the acquisition is expected to positively influence the company's operational performance [3]

资料显示，康录生物专注于荧光原位杂交（FISH）细分领域和PCR等分子诊断领域的拓展，致力于实 现FISH检测的快速化、自动化和智能化整体解决方案，目前已实现FISH试剂快速化，检测设备自动化 的研发生产和销售。 北京商报讯（记者 丁宁）8月4日晚间，透景生命（300642）发布公告称，公司拟先行收购武汉康录生 物技术股份有限公司（以下简称"康录生物"）72.86%的股份，交易金额为2.91亿元。在公司收购康录生 物72.86%股份完成后，康录生物将成为公司控股子公司，纳入公司合并报表范围。2026年及2027年， 若满足本次交易有关协议约定的前置条件，公司将进一步向陈刚和谢俊收购其所持康录生物约9.14%的 股份，交易金额为3654.81万元。前述三步收购完成后，公司将合计持有康录生物82%股份。公司本次 交易总金额合计3.28亿元。 ...

Core Viewpoint - The company intends to acquire 72.8630% of Wuhan Kanglu Biological Technology Co., Ltd., which will become a subsidiary and included in the company's consolidated financial statements after the acquisition is completed [1][2] Group 1: Acquisition Details - The transaction amount for acquiring 72.8630% of Kanglu Biological is RMB 291 million [1] - If certain conditions are met in 2026 and 2027, the company plans to acquire an additional 9.1370% of Kanglu Biological from Chen Gang and Xie Jun, with a transaction amount of RMB 36.5481 million based on asset valuation reports [1] Group 2: Business and Strategic Implications - Kanglu Biological focuses on the fluorescence in situ hybridization (FISH) and PCR molecular diagnostics fields, aiming for rapid, automated, and intelligent solutions [2] - The company has developed and sold rapid FISH reagents and automated detection equipment, holding proprietary technology for FastProbe® rapid FISH probe preparation [2] - The acquisition is expected to create synergies in development strategy, market channels, products, and technology, enhancing the company's overall competitiveness and providing new revenue and profit growth opportunities [2]

Group 1 - The company plans to acquire 72.8630% of Wuhan Kanglu Biological Technology Co., Ltd. for a transaction amount of RMB 291 million, which will make Kanglu a subsidiary included in the company's consolidated financial statements [1] - Following the initial acquisition, the company intends to purchase an additional 9.1370% of Kanglu's shares in 2026 and 2027, contingent upon meeting certain preconditions, with a transaction amount of RMB 36.5481 million [1] - Upon completion of all transactions, the company will hold a total of 82.00% of Kanglu's shares [1] Group 2 - Kanglu focuses on the fluorescence in situ hybridization (FISH) and PCR molecular diagnostics fields, aiming for rapid, automated, and intelligent solutions in FISH detection [2] - The company has developed and commercialized rapid FISH reagents and automated detection equipment, possessing proprietary technology for FastProbe rapid FISH probe preparation [2] - The acquisition is expected to create synergies in strategic development, market channels, products, and technology, enhancing the company's overall competitiveness and providing new revenue and profit growth opportunities [2]

（文章来源：每日经济新闻） 2024年1至12月份，透景生命的营业收入构成为：体外诊断行业占比100.0%。 透景生命（SZ 300642，收盘价：18.08元）8月4日晚间发布公告称，上海透景生命科技股份有限公司拟 先行收购武汉康录生物技术股份有限公司约72.86%的股份。在公司收购康录生物约72.86%股份完成 后，康录生物将成为公司控股子公司，纳入公司合并报表范围。2026年及2027年，若满足本次交易有关 协议约定的前置条件，公司将进一步向陈刚和谢俊收购其所持康录生物约9.14%的股份，前述三步收购 完成后，公司将合计持有康录生物82%股份。 ...

每经头条（nbdtoutiao）——理想i8和乘龙卡车对撞测试，由中国汽研"操刀"！权威机构如何确保权威， 测试要不要公证？业内人士解读 （记者 胡玲） 2024年1至12月份，透景生命的营业收入构成为：体外诊断行业占比100.0%。 截至发稿，透景生命市值为29亿元。 每经AI快讯，透景生命（SZ 300642，收盘价：18.08元）8月4日晚间发布公告称，公司第四届第十一次 董事会临时会议于2025年8月1日在上海市浦东新区汇庆路412号公司会议室以现场结合通讯会议的方式 召开。会议审议了《关于收购武汉康录生物技术股份有限公司控股权的议案》等文件。 ...

转自：智通财经 【透景生命：拟收购康录生物控股权】智通财经8月4日电，透景生命(300642.SZ)公告称，公司拟先行 收购武汉康录生物技术股份有限公司（72.8630%的股份。在公司收购康录生物72.8630%股份完成后， 康录生物将成为公司控股子公司，纳入公司合并报表范围。2026年及2027年，若满足本次交易有关协议 约定的前置条件，公司将进一步向陈刚和谢俊收购其所持康录生物9.1370%的股份，前述三步收购完成 后，公司将合计持有康录生物82.00%股份。 ...

Group 1 - The company plans to acquire 72.8630% of Wuhan Kanglu Biological Technology Co., Ltd. [1] - Upon completion of the acquisition, Kanglu Bio will become a subsidiary of the company and will be included in the company's consolidated financial statements [1] - In 2026 and 2027, the company intends to acquire an additional 9.1370% of Kanglu Bio from Chen Gang and Xie Jun, potentially increasing its total ownership to 82.00% [1]

证券代码：300642 证券简称：透景生命 公告编号：2025-052 上海透景生命科技股份有限公司 关于收购武汉康录生物技术股份有限公司控股权的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、上海透景生命科技股份有限公司（以下简称"公司"或"透景生命"） 拟先行收购武汉康录生物技术股份有限公司（以下简称"康录生物"、"标的公 司"或"交易标的"）72.8630%的股份。在公司收购康录生物 72.8630%股份完 成后，康录生物将成为公司控股子公司，纳入公司合并报表范围。2026 年及 2027 年，若满足本次交易有关协议约定的前置条件，公司将进一步向陈刚和谢俊收购 其所持康录生物 9.1370%的股份，前述三步收购完成后，公司将合计持有康录生 物 82.00%股份。 2、本次交易股份转让的价格以银信资产评估有限公司出具的资产评估报告 （银信评报字(2025)第 050129 号）为定价参考依据，经交易各方协商确定，本 次收购康录生物 72.8630%股份的交易金额为人民币 29,145.19 万元；2026 年及 2027 年，若满足本 ...

证券代码：300642 证券简称：透景生命 公告编号：2025-050 上海透景生命科技股份有限公司 关于第四届董事会第十一次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、上海透景生命科技股份有限公司（以下简称"公司"）第四届董事会第 十一次（临时）会议（以下简称"本次会议"）通知于 2025 年 07 月 25 日通过 邮件或专人送达的方式通知公司全体董事。 2、本次会议于 2025 年 08 月 01 日在上海市浦东新区汇庆路 412 号公司会议 室以现场结合通讯会议的方式召开。 1、审议通过《关于收购武汉康录生物技术股份有限公司控股权的议案》 为补充公司在分子病理领域的布局、提升公司在肿瘤诊断领域的竞争优势， 持续增强核心竞争力，董事会同意公司于 2025 年、2026 年、2027 年以收购总价 32,800 万元收购陈刚、谢俊、苏州工业园区新建元二期创业投资企业（有限合 伙）等 17 名武汉康录生物技术股份有限公司（以下简称"康录生物"）股东合 计持有康录生物 82.00%的股权。其中，在首次交易阶段（2 ...